Insmed Inc (INSM)

[coinstarz]

Young said in the CC was about NDA (new drug application) in EU. It was not orphan application. They have been filing orphan since 2003 for diff indications. However, it was the first time they filed for orphan for primary IGFD using iPlex. I think orphan has nothing to do with approval NDA, it just gives 7-yr copy right protection. For ex, INSM filed orphan in U.S. long time ago before submitted NDA to FDA in late 2004.

Increlex got orphan too but it doesn't mean EU will approve it if they read Dr. Underwood's testimony or read through i-box. I might send EU i-hub link...lol